Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology · 2009
[Evaluation of alpha-normiks (rifaximin) efficacy in the treatment of patients with diverticular disease associated with medium and severe intestinal dysbacteriosis].
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lutkov I V
Аннотация
THE PURPOSE OF THE STUDY: to evaluate the efficacy of using rifaksimin drug within complex therapy of patients with the disease and diverticular intestinal dysbacteriosis.
MATERIALS AND METHODS: 57 patients participated with a moderate exacerbation of the disease, they were divided equally on the composition of the group--two control and one under study. Patients in the control groups were composed of complex treatment of oral antibacterial drugs, or bacteriophage, the investigated group of patients--rifaksimin. We evaluated the dynamics of clinical symptoms, analysis of stool for dysbacteriosis and biochemical parameters.
RESULTS: detected superior effectiveness of the Alpha-normiks drug in the treatment of patients with colon pathologies investigated in comparison with the use of oral antibacterial drugs, or bacteriophages. Proved the high safety of treatment with using of rifaksimin.
CONCLUSIONS: The preparation of Alpha-normiks may be appointed with great success at patients with diverticular disease, and with intestinal dysbacteriosis.
MATERIALS AND METHODS: 57 patients participated with a moderate exacerbation of the disease, they were divided equally on the composition of the group--two control and one under study. Patients in the control groups were composed of complex treatment of oral antibacterial drugs, or bacteriophage, the investigated group of patients--rifaksimin. We evaluated the dynamics of clinical symptoms, analysis of stool for dysbacteriosis and biochemical parameters.
RESULTS: detected superior effectiveness of the Alpha-normiks drug in the treatment of patients with colon pathologies investigated in comparison with the use of oral antibacterial drugs, or bacteriophages. Proved the high safety of treatment with using of rifaksimin.
CONCLUSIONS: The preparation of Alpha-normiks may be appointed with great success at patients with diverticular disease, and with intestinal dysbacteriosis.